Levels of oxidized LDL and advanced glycation end products - Modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes

Diabetes

Volumn 60, Issue 2, 2011, Pages 582-589

  Lopes Virella, Maria F ^a,b   Hunt, Kelly J ^a   Baker, Nathaniel L ^a   Lachin, John ^c   Nathan, David M ^d   Virella, G ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; LOW DENSITY LIPOPROTEIN; MALONDIALDEHYDE MODIFIED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIGEN ANTIBODY COMPLEX; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BLOOD VESSEL PARAMETERS; BODY MASS; CARDIOVASCULAR RISK; COMMON CAROTID ARTERY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTENSIVE CARE; INTERNAL CAROTID ARTERY; INTIMA MEDIA THICKNESS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ANTIGEN-ANTIBODY COMPLEX; CAROTID ARTERIES; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPOPROTEINS, LDL; LOGISTIC MODELS; MALE; MALONDIALDEHYDE; RISK FACTORS; TUNICA INTIMA; TUNICA MEDIA;

EID: 79551586291     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-0915     Document Type: Article

References (38)

1. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-874
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126
3. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002;8:1211-1217 (Pubitemid 35373551)
4. Drake TA, Hannani K, Fei H, Lavi S, Berliner JA. Minimally oxidized low-density lipo-protein induces tissue factor expression in cultured human endothelial cells. Am J Pathol 1991;138:601-607
5. Kusuhara M, Chait A, Cader A, Berk BC. Oxidized LDL stimulates mitogen-activated protein kinases in smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 1997;17:141-148
6. Liao F, Berliner JA, Mehrabian M, et al. Minimally modified low density lipoprotein is biologically active in vivo in mice. J Clin Invest 1991;87:2253-2257
7. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987;84:2995-2998
8. Ylä-Herttuala S. Biochemistry of the arterial wall in developing atherosclerosis. Ann N Y Acad Sci 1991;623:40-59
9. Terkeltaub R, Banka CL, Solan J, Santoro D, Brand K, Curtiss LK. Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. Arterioscler Thromb 1994;14:47-53
10. Hazen SL. Oxidized phospholipids as endogenous pattern recognition ligands in innate immunity. J Biol Chem 2008;283:15527-15531
11. Virella G, Lopes-Virella MF. Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis 2008;200:239-246
12. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol 2010;134:33-46
13. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 1995;92:3893-3897
14. Virella G, Lopes-Virella MF. Lipoprotein autoantibodies: measurement and significance. Clin Diagn Lab Immunol 2003;10:499-505
15. Virella G, Thorpe SR, Alderson NL, et al. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J Lipid Res 2004;45:1859-1867 (Pubitemid 40990878)
16. Ylä-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086-1095
17. Ylä-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994;14:32-40
18. Mironova M, Virella G, Lopes-Virella MF. Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb Vasc Biol 1996;16:222-229
19. Virella G, Carter RE, Saad A, Crosswell EG, Game BA, Lopes-Virella MF; DCCT/EDIC Study Group. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin Immunol 2008;127:394-400
20. Saad AF, Virella G, Chassereau C, Boackle RJ, Lopes-Virella MF. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res 2006;47:1975-1983
21. Virella G, Derrick MB, Pate V, Chassereau C, Thorpe SR, Lopes-Virella MF. Development of capture assays for different modifications of human low-density lipoprotein. Clin Diagn Lab Immunol 2005;12:68-75
22. Mironova M, Virella G, Virella-Lowell I, Lopes-Virella MF. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin Immunol Immunopathol 1997;85:73-82 (Pubitemid 27432005)
23. Mironova MA, Klein RL, Virella GT, Lopes-Virella MF. Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes 2000;49:1033-1041
24. Lopes-Virella MF, Virella G, Orchard TJ, et al. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol 1999;90:165-172
25. Orchard TJ, Virella G, Forrest KY, Evans RW, Becker DJ, Lopes-Virella MF. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: A nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1999;48:1454-1458
26. Lopes-Virella MF, McHenry MB, Lipsitz S, et al; DCCT/EDIC Research Group. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 2007;190:359-369
27. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
28. Epidemiology of Diabetes Interventions and Complications (EDIC). Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99-111
29. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intimamedia thickness in predicting clinical coronary events. Ann Intern Med 1998;128:262-269
30. Nathan DM, Lachin J, Cleary P, et al; Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003;348:2294-2303
31. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Diabetes 1999;48:383-390
32. The DCCT Research Group. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. Clin Chem 1987;33:2267-2271
33. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991;98(Suppl. 5):823-833
34. Virella G, Tsokos G. Immune complex diseases. In Medical Immunology. Virella G, Ed. London, NY, Informa, 2007, p. 323-334
35. Virella G, Koskinen S, Krings G, Onorato JM, Thorpe SR, Lopes-Virella M. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin Immunol 2000;95:135-144
36. Virella G, Thorpe SR, Alderson NL, et al. Autoimmune response to advanced glycosylation end-products of human LDL. J Lipid Res 2003;443:487-493 (Pubitemid 37279696)
37. Michaelsen TE, Sandlie I, Bratlie DB, Sandin RH, Ihle O. Structural difference in the complement activation site of human IgG1 and IgG3. Scand J Immunol 2009;70:553-564
38. Burton DR, Woof JM. Human antibody effector function. Adv Immunol 1992;51:1-84